Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	voltage-gated sodium channel activity	SCN4A SCN5A	3.37e-04	26	21	2	GO:0005248
GeneOntologyMolecularFunction	sodium ion transmembrane transporter activity	SCN4A SCN5A SLC12A1	7.33e-04	171	21	3	GO:0015081
GeneOntologyMolecularFunction	sodium channel activity	SCN4A SCN5A	1.35e-03	52	21	2	GO:0005272
GeneOntologyMolecularFunction	scaffold protein binding	IL6ST SCN5A	4.25e-03	93	21	2	GO:0097110
GeneOntologyMolecularFunction	monoatomic cation transmembrane transporter activity	P2RX2 SCN4A SCN5A SLC12A1	4.62e-03	664	21	4	GO:0008324
GeneOntologyMolecularFunction	monoatomic cation channel activity	P2RX2 SCN4A SCN5A	5.31e-03	343	21	3	GO:0005261
GeneOntologyMolecularFunction	transmembrane transporter activity	P2RX2 ABCA8 SCN4A SCN5A SLC12A1	6.57e-03	1180	21	5	GO:0022857
GeneOntologyMolecularFunction	monoatomic ion transmembrane transporter activity	P2RX2 SCN4A SCN5A SLC12A1	8.61e-03	793	21	4	GO:0015075
GeneOntologyMolecularFunction	transporter activity	P2RX2 ABCA8 SCN4A SCN5A SLC12A1	9.49e-03	1289	21	5	GO:0005215
GeneOntologyMolecularFunction	growth factor binding	IL6ST SCN5A	1.16e-02	156	21	2	GO:0019838
GeneOntologyMolecularFunction	monoatomic ion channel activity	P2RX2 SCN4A SCN5A	1.18e-02	459	21	3	GO:0005216
GeneOntologyMolecularFunction	metal ion transmembrane transporter activity	SCN4A SCN5A SLC12A1	1.22e-02	465	21	3	GO:0046873
GeneOntologyBiologicalProcess	neuronal action potential	P2RX2 SCN4A SCN5A	3.47e-05	63	21	3	GO:0019228
GeneOntologyCellularComponent	voltage-gated sodium channel complex	SCN4A SCN5A	1.30e-04	17	21	2	GO:0001518
GeneOntologyCellularComponent	endoplasmic reticulum membrane	TRAM2 REEP3 ZDHHC20 TMEM39B DIPK1A DOLK PIGC	1.84e-04	1293	21	7	GO:0005789
GeneOntologyCellularComponent	endoplasmic reticulum subcompartment	TRAM2 REEP3 ZDHHC20 TMEM39B DIPK1A DOLK PIGC	1.89e-04	1299	21	7	GO:0098827
GeneOntologyCellularComponent	nuclear outer membrane-endoplasmic reticulum membrane network	TRAM2 REEP3 ZDHHC20 TMEM39B DIPK1A DOLK PIGC	2.16e-04	1327	21	7	GO:0042175
GeneOntologyCellularComponent	sodium channel complex	SCN4A SCN5A	3.84e-04	29	21	2	GO:0034706
HumanPheno	Congestive heart failure	XYLT2 IL6ST SCN4A SCN5A DOLK	2.28e-05	278	8	5	HP:0001635
HumanPheno	Apneic episodes in infancy	SCN4A SCN5A	9.65e-05	10	8	2	HP:0005949
HumanPheno	Fetal onset	IL6ST SCN4A SCN5A SLC12A1	1.37e-04	198	8	4	HP:0011461
HumanPheno	Abnormal atrioventricular valve physiology	XYLT2 IL6ST SCN4A SCN5A	1.89e-04	215	8	4	HP:0031650
HumanPheno	Hypokalemia	SCN4A SCN5A SLC12A1	1.90e-04	79	8	3	HP:0002900
Domain	Na_channel_asu	SCN4A SCN5A	4.88e-05	10	20	2	IPR001696
Domain	Na_trans_assoc	SCN4A SCN5A	4.88e-05	10	20	2	IPR010526
Domain	Na_trans_assoc	SCN4A SCN5A	4.88e-05	10	20	2	PF06512
Domain	Channel_four-helix_dom	SCN4A SCN5A	1.68e-03	57	20	2	IPR027359
Domain	-	SCN4A SCN5A	1.68e-03	57	20	2	1.20.120.350
Domain	IQ	SCN4A SCN5A	3.36e-03	81	20	2	SM00015
Domain	IQ_motif_EF-hand-BS	SCN4A SCN5A	4.12e-03	90	20	2	IPR000048
Domain	IQ	SCN4A SCN5A	4.40e-03	93	20	2	PS50096
Domain	Ion_trans_dom	SCN4A SCN5A	6.53e-03	114	20	2	IPR005821
Domain	Ion_trans	SCN4A SCN5A	6.53e-03	114	20	2	PF00520
Pathway	REACTOME_INTERACTION_BETWEEN_L1_AND_ANKYRINS	SCN4A SCN5A	3.60e-04	31	13	2	M877
Pathway	REACTOME_PHASE_0_RAPID_DEPOLARISATION	SCN4A SCN5A	3.83e-04	32	13	2	M27455
Pubmed	Mouse heart Na+ channels: primary structure and function of two isoforms and alternatively spliced variants.	SCN4A SCN5A	3.47e-07	2	21	2	11834499
Pubmed	Ca2+-dependent regulation of sodium channels NaV1.4 and NaV1.5 is controlled by the post-IQ motif.	SCN4A SCN5A	3.47e-07	2	21	2	30944319
Pubmed	Modulation of skeletal and cardiac voltage-gated sodium channels by calmodulin.	SCN4A SCN5A	1.04e-06	3	21	2	15746172
Pubmed	Human voltage-gated sodium channel mutations that cause inherited neuronal and muscle channelopathies increase resurgent sodium currents.	SCN4A SCN5A	1.04e-06	3	21	2	20038812
Pubmed	Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels.	SCN4A SCN5A	3.47e-06	5	21	2	17724025
Pubmed	Interaction of muscle and brain sodium channels with multiple members of the syntrophin family of dystrophin-associated proteins.	SCN4A SCN5A	9.70e-06	8	21	2	9412493
Pubmed	International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels.	SCN4A SCN5A	1.25e-05	9	21	2	16382098
Pubmed	Expression pattern of neuronal and skeletal muscle voltage-gated Na+ channels in the developing mouse heart.	SCN4A SCN5A	1.25e-05	9	21	2	15746173
Pubmed	Large-scale analysis of ion channel gene expression in the mouse heart during perinatal development.	P2RX2 SCN4A SCN5A	7.88e-05	139	21	3	16985003
Pubmed	Uncovering quantitative protein interaction networks for mouse PDZ domains using protein microarrays.	SCN4A SCN5A	8.72e-05	23	21	2	16637659
Pubmed	Genome-wide association study of plasma N6 polyunsaturated fatty acids within the cohorts for heart and aging research in genomic epidemiology consortium.	PTCHD4 REEP3	4.88e-04	54	21	2	24823311
Interaction	POMK interactions	XYLT2 TMEM39B DIPK1A SCN4A	1.31e-04	271	20	4	int:POMK
Interaction	CHRNB2 interactions	P2RX2 TMEM39B DIPK1A	1.39e-04	103	20	3	int:CHRNB2
Interaction	KCNA6 interactions	HERC3 DOLK	1.58e-04	19	20	2	int:KCNA6
Interaction	SCN8A interactions	SCN4A SCN5A	1.76e-04	20	20	2	int:SCN8A
Interaction	TMEM219 interactions	DIPK1A SCN4A	2.34e-04	23	20	2	int:TMEM219
Interaction	TMEM62 interactions	HERC3 SCN4A	2.55e-04	24	20	2	int:TMEM62
Cytoband	Ensembl 112 genes in cytogenetic band chr6p12	TRAM2 PTCHD4	1.92e-03	142	21	2	chr6p12
GeneFamily	Sodium voltage-gated channel alpha subunits	SCN4A SCN5A	1.45e-05	9	12	2	1203
Coexpression	DOUGLAS_BMI1_TARGETS_UP	TRAM2 XYLT2 ZDHHC20 IL6ST EIF4E3 TMEM268	3.94e-06	563	21	6	M15103
Coexpression	GSE17301_IFNA2_VS_IFNA2_AND_ACD3_ACD28_STIM_CD8_TCELL_UP	TRAM2 XYLT2 DIPK1A TMEM268	1.78e-05	200	21	4	M8042
Coexpression	ZHENG_BOUND_BY_FOXP3	REEP3 ZDHHC20 DIPK1A IL6ST HERC3	3.84e-05	498	21	5	M1741
Coexpression	ZHENG_BOUND_BY_FOXP3	REEP3 ZDHHC20 DIPK1A IL6ST HERC3	4.18e-05	507	21	5	MM1030
Computational	Genes in the cancer module 400.	ABCA8 IL6ST	1.93e-04	19	12	2	MODULE_400
Drug	Flecainide	SCN4A SCN5A	8.10e-07	2	21	2	DB01195
Drug	Hydrochlorothiazide [58-93-5]; Down 200; 13.4uM; PC3; HT_HG-U133A	XYLT2 ITFG2 TMEM268 PIGC	2.68e-05	193	21	4	6625_DN
Drug	prochlorperazine dimaleate salt; Down 200; 10uM; MCF7; HT_HG-U133A	TRAM2 XYLT2 ITFG2 PIGC	3.08e-05	200	21	4	5212_DN
Drug	tetrapentylammonium	SCN4A SCN5A	1.09e-04	17	21	2	CID000017248
Drug	Zonisamide	SCN4A SCN5A	1.09e-04	17	21	2	DB00909
Drug	methanethiosulfonate	P2RX2 SCN4A SCN5A	1.13e-04	103	21	3	CID004188587
Drug	moricizine	SCN4A SCN5A	1.23e-04	18	21	2	CID000034632
Drug	AC1L1MOZ	SCN4A SCN5A	2.80e-04	27	21	2	CID000031958
Drug	DPI 201-106	SCN4A SCN5A	3.02e-04	28	21	2	CID000005190
Drug	encainide	SCN4A SCN5A	3.02e-04	28	21	2	CID000048040
Drug	tocainide	SCN4A SCN5A	3.47e-04	30	21	2	CID000038945
Drug	oxcarbazepine	SCN4A SCN5A	3.47e-04	30	21	2	CID000034312
Drug	NSC15627	SCN4A SCN5A	4.47e-04	34	21	2	CID000002073
Drug	kojic acid	TRAM2 ZDHHC20 IL6ST TMEM217	5.52e-04	424	21	4	ctd:C011890
Drug	ranolazine	SCN4A SCN5A	5.88e-04	39	21	2	CID000056959
Drug	Lidocaone hydrochloride [73-78-9]; Down 200; 14.8uM; MCF7; HT_HG-U133A	XYLT2 IL6ST PIGC	6.81e-04	190	21	3	4421_DN
Drug	Benoxinate hydrochloride [5987-82-6]; Down 200; 11.6uM; MCF7; HT_HG-U133A	XYLT2 ITFG2 PIGC	6.81e-04	190	21	3	4115_DN
Drug	Sulfamethazine sodium salt [1981-58-4]; Down 200; 13.4uM; PC3; HT_HG-U133A	XYLT2 IL6ST HERC3	6.81e-04	190	21	3	4322_DN
Drug	Chloroquine diphosphate [50-63-5]; Down 200; 7.8uM; MCF7; HT_HG-U133A	XYLT2 ITFG2 IL6ST	6.81e-04	190	21	3	2869_DN
Drug	heptanol	SCN4A SCN5A	6.82e-04	42	21	2	CID000008129
Drug	Rapamycin; Down 200; 0.1uM; MCF7; HT_HG-U133A	ITFG2 TMEM39B PIGC	6.91e-04	191	21	3	5204_DN
Drug	fluphenazine dihydrochloride; Down 200; 10uM; MCF7; HT_HG-U133A	TRAM2 ITFG2 PIGC	6.91e-04	191	21	3	5234_DN
Drug	Demeclocycline hydrochloride [64-73-3]; Down 200; 8uM; PC3; HT_HG-U133A	XYLT2 DIPK1A IL6ST	7.02e-04	192	21	3	4267_DN
Drug	vinblastine sulfate; Up 200; 0.1uM; PC3; HT_HG-U133A	XYLT2 DIPK1A IL6ST	7.02e-04	192	21	3	7556_UP
Drug	N-Acetyl-DL-homocysteine Thiolactone [1195-16-0]; Down 200; 25.2uM; PC3; HT_HG-U133A	XYLT2 IL6ST PIGC	7.02e-04	192	21	3	4311_DN
Drug	Bisacodyl [603-50-9]; Down 200; 11uM; PC3; HT_HG-U133A	DIPK1A DOLK TMEM268	7.13e-04	193	21	3	4616_DN
Drug	Astemizole [68844-77-9]; Down 200; 8.8uM; PC3; HT_HG-U133A	ITFG2 DIPK1A DOLK	7.13e-04	193	21	3	2049_DN
Drug	Fluvastatin sodium salt [93957-55-2]; Down 200; 9.2uM; PC3; HT_HG-U133A	ITFG2 DIPK1A IL6ST	7.13e-04	193	21	3	6691_DN
Drug	Clemizole hydrochloride [1163-36-6]; Down 200; 11uM; PC3; HT_HG-U133A	DIPK1A TMEM268 PIGC	7.13e-04	193	21	3	7371_DN
Drug	Alexidine dihydrochloride [22573-93-9]; Down 200; 6.8uM; MCF7; HT_HG-U133A	TRAM2 ITFG2 DOLK	7.23e-04	194	21	3	4721_DN
Drug	Kynurenine, 3-hydroxy (R,S) [2147-61-7]; Down 200; 17.8uM; MCF7; HT_HG-U133A	XYLT2 ITFG2 HERC3	7.23e-04	194	21	3	5641_DN
Drug	alpha-Santonin [481-06-1]; Up 200; 16.2uM; PC3; HT_HG-U133A	P2RX2 DIPK1A SCN4A	7.23e-04	194	21	3	4531_UP
Drug	Chlorpromazine hydrochloride [69-09-0]; Down 200; 11.2uM; MCF7; HT_HG-U133A	XYLT2 ITFG2 IL6ST	7.34e-04	195	21	3	1700_DN
Drug	Gabapentin [60142-96-3]; Up 200; 23.4uM; MCF7; HT_HG-U133A	ITFG2 IL6ST HERC3	7.34e-04	195	21	3	3472_UP
Drug	Cephalexin monohydrate [23325-78-2]; Up 200; 11uM; HL60; HT_HG-U133A	TRAM2 XYLT2 ITFG2	7.34e-04	195	21	3	1273_UP
Drug	Nefopam hydrochloride [23327-57-3]; Down 200; 13.8uM; HL60; HT_HG-U133A	XYLT2 TMEM268 PIGC	7.34e-04	195	21	3	2355_DN
Drug	Sulfapyridine [144-83-2]; Down 200; 16uM; MCF7; HT_HG-U133A	ITFG2 TMEM39B IL6ST	7.34e-04	195	21	3	6799_DN
Drug	Amprolium hydrochloride [137-88-2]; Up 200; 12.6uM; MCF7; HT_HG-U133A	XYLT2 ITFG2 PIGC	7.45e-04	196	21	3	1479_UP
Drug	Aceclofenac [89796-99-6]; Up 200; 11.2uM; PC3; HT_HG-U133A	ITFG2 DIPK1A PIGC	7.45e-04	196	21	3	7269_UP
Drug	CP-863187 [668981-07-5]; Up 200; 10uM; PC3; HT_HG-U133A	XYLT2 ITFG2 IL6ST	7.45e-04	196	21	3	7558_UP
Drug	Hydrocortisone base [50-23-7]; Down 200; 11uM; PC3; HT_HG-U133A	ITFG2 IL6ST PIGC	7.45e-04	196	21	3	6684_DN
Drug	Epicatechin-(-) [154-23-4]; Down 200; 13.8uM; PC3; HT_HG-U133A	ITFG2 DIPK1A HERC3	7.45e-04	196	21	3	4594_DN
Drug	Epitiostanol [2363-58-8]; Down 200; 13uM; HL60; HT_HG-U133A	HERC3 DOLK PIGC	7.45e-04	196	21	3	2922_DN
Drug	Alverine citrate salt [5560-59-8]; Up 200; 8.4uM; PC3; HT_HG-U133A	ITFG2 HERC3 PIGC	7.56e-04	197	21	3	2110_UP
Drug	2-propylpentanoic acid; Down 200; 500uM; MCF7; HT_HG-U133A	XYLT2 ITFG2 PIGC	7.56e-04	197	21	3	5600_DN
Drug	Thioridazine hydrochloride [130-61-0]; Down 200; 9.8uM; MCF7; HT_HG-U133A	TRAM2 XYLT2 IL6ST	7.56e-04	197	21	3	1486_DN
Drug	Scopolamin-N-oxide hydrobromide [6106-81-6]; Down 200; 10uM; MCF7; HT_HG-U133A	XYLT2 ITFG2 IL6ST	7.56e-04	197	21	3	5436_DN
Drug	Harmaline hydrochloride dihydrate [6027-98-1]; Down 200; 14uM; PC3; HT_HG-U133A	XYLT2 ITFG2 IL6ST	7.56e-04	197	21	3	6623_DN
Drug	Chlorthalidone [77-36-1]; Down 200; 11.8uM; MCF7; HT_HG-U133A	TRAM2 ITFG2 PIGC	7.56e-04	197	21	3	6800_DN
Drug	Heliotrine [303-33-3]; Down 200; 12.8uM; HL60; HT_HG-U133A	XYLT2 DOLK PIGC	7.56e-04	197	21	3	2180_DN
Drug	Aceclofenac [89796-99-6]; Up 200; 11.2uM; PC3; HT_HG-U133A	ITFG2 IL6ST HERC3	7.56e-04	197	21	3	2117_UP
Drug	Sulfadiazine [68-35-9]; Down 200; 16uM; PC3; HT_HG-U133A	DIPK1A DOLK TMEM268	7.56e-04	197	21	3	5098_DN
Drug	Hydrocortisone base [50-23-7]; Up 200; 11uM; MCF7; HT_HG-U133A	ITFG2 SCN4A PIGC	7.68e-04	198	21	3	5284_UP
Drug	Zalcitabine [7481-89-2]; Down 200; 19uM; PC3; HT_HG-U133A	DIPK1A TMEM268 PIGC	7.68e-04	198	21	3	4215_DN
Drug	Nitrendipine [39562-70-4]; Up 200; 11uM; PC3; HT_HG-U133A	ABCA8 IL6ST HERC3	7.68e-04	198	21	3	6304_UP
Drug	2-propylpentanoic acid; Down 200; 50uM; MCF7; HT_HG-U133A	ITFG2 DIPK1A PIGC	7.68e-04	198	21	3	5219_DN
Drug	Bromopride [4093-35-0]; Down 200; 11.6uM; HL60; HT_HG-U133A	XYLT2 HERC3 PIGC	7.68e-04	198	21	3	2182_DN
Drug	Todralazine hydrochloride [3778-76-5]; Up 200; 14.8uM; PC3; HT_HG-U133A	XYLT2 DIPK1A SCN4A	7.68e-04	198	21	3	5087_UP
Drug	Metampicillin sodium salt [6489-61-8]; Down 200; 10.4uM; MCF7; HT_HG-U133A	ITFG2 HERC3 PIGC	7.68e-04	198	21	3	2286_DN
Drug	Cefaclor [70356-03-5]; Down 200; 10.4uM; PC3; HT_HG-U133A	ITFG2 IL6ST PIGC	7.68e-04	198	21	3	6622_DN
Drug	Felbinac [5728-52-9]; Down 200; 18.8uM; MCF7; HT_HG-U133A	ITFG2 HERC3 PIGC	7.68e-04	198	21	3	3398_DN
Drug	Bretylium tosylate [61-75-6]; Down 200; 9.6uM; PC3; HT_HG-U133A	ITFG2 DIPK1A HERC3	7.79e-04	199	21	3	6674_DN
Drug	Sulfamethizole [144-82-1]; Up 200; 14.8uM; MCF7; HT_HG-U133A	ITFG2 IL6ST PIGC	7.79e-04	199	21	3	6272_UP
Drug	Torsemide [56211-40-6]; Up 200; 11.4uM; MCF7; HT_HG-U133A	ITFG2 SCN5A PIGC	7.79e-04	199	21	3	5476_UP
Drug	haloperidol; Down 200; 10uM; MCF7; HT_HG-U133A	TRAM2 XYLT2 ITFG2	7.79e-04	199	21	3	6923_DN
Drug	Nitrofurantoin [67-20-9]; Down 200; 16.8uM; PC3; HT_HG-U133A	ITFG2 TMEM268 PIGC	7.79e-04	199	21	3	7373_DN
Drug	Sulfisoxazole [127-69-5]; Up 200; 15uM; HL60; HG-U133A	ITFG2 TMEM39B SCN5A	7.79e-04	199	21	3	1603_UP
Drug	Niacin [59-67-6]; Down 200; 32.4uM; PC3; HT_HG-U133A	DIPK1A IL6ST TMEM268	7.79e-04	199	21	3	6702_DN
Drug	Methimazole [60-56-0]; Down 200; 35uM; MCF7; HT_HG-U133A	XYLT2 ITFG2 IL6ST	7.90e-04	200	21	3	3432_DN
Drug	Nadolol [42200-33-9]; Down 200; 13uM; HL60; HT_HG-U133A	SCN5A DOLK PIGC	7.90e-04	200	21	3	3020_DN
Drug	Aminopurine, 6-benzyl [1214-39-7]; Up 200; 17.8uM; MCF7; HT_HG-U133A	ITFG2 P2RX2 SCN5A	7.90e-04	200	21	3	3623_UP
Drug	Sulfapyridine [144-83-2]; Down 200; 16uM; PC3; HT_HG-U133A	XYLT2 DIPK1A IL6ST	7.90e-04	200	21	3	7151_DN
Drug	pilsicainide	SCN4A SCN5A	8.18e-04	46	21	2	CID000004820
Disease	generalized epilepsy with febrile seizures plus 2 (implicated_via_orthology)	SCN4A SCN5A	2.16e-05	10	21	2	DOID:0111294 (implicated_via_orthology)
Disease	Dravet syndrome (implicated_via_orthology)	SCN4A SCN5A	2.16e-05	10	21	2	DOID:0080422 (implicated_via_orthology)
Disease	generalized epilepsy with febrile seizures plus (implicated_via_orthology)	SCN4A SCN5A	3.17e-05	12	21	2	DOID:0060170 (implicated_via_orthology)
Disease	epilepsy (implicated_via_orthology)	SCN4A SCN5A SLC12A1	2.05e-04	163	21	3	DOID:1826 (implicated_via_orthology)
Disease	Familial dilated cardiomyopathy	SCN5A DOLK	4.48e-04	44	21	2	C0340427
Disease	total cholesterol measurement, triglyceride measurement, low density lipoprotein cholesterol measurement, high density lipoprotein cholesterol measurement	TRAM2 PIGC	5.56e-04	49	21	2	EFO_0004530, EFO_0004574, EFO_0004611, EFO_0004612

Protein segments in the cluster

Peptide	Gene	Start	Entry
SWNTYYTNTEFVIVV	ARL5A	76	Q9Y689
AVALAVQAFYVQYKW	DOLK	46	Q9UPQ8
YVFQISVHEWYTAFS	HERC3	896	Q15034
YVTFNQKIYVYWEVQ	ITFG2	371	Q969R8
IYTVQTVQIFWSVYN	EIF4E3	76	Q8N5X7
FVWYVFIVQKSYQES	P2RX2	56	Q9UBL9
YSTVYFVNIEVWVEA	IL6ST	186	P40189
VFVGSWIIYVQYSTY	DIPK1A	36	Q5T7M9
YFTVGWNIFDFVVVI	SCN4A	1411	P35499
TAVSWVEQYYQFLKV	PTCHD4	546	Q6ZW05
YFTNSWNIFDFVVVI	SCN5A	1586	Q14524
WAAVITYVIEFFLYV	SLC12A1	626	Q13621
YQYWAVVFESSVVIQ	PIGC	46	Q92535
YWIVFALYTVIETVA	REEP3	41	Q6NUK4
IWSFCFYVVTVFSVA	ABCA8	1136	O94911
FAVVFYVVVWANIYS	TMEM268	106	Q5VZI3
FITFVVVWSYYAYVV	ZDHHC20	21	Q5W0Z9
VVWSYYAYVVELCVF	ZDHHC20	26	Q5W0Z9
VVFHFTSVIWCFYVV	TRAM2	121	Q15035
IYIVWIFFYETANVV	TMEM217	96	Q8N7C4
WFVLTRSFVEYVVYT	XYLT2	401	Q9H1B5
SAYYVAFVPVWFVKN	TMEM39B	296	Q9GZU3